Aegerion Resolves FDA Warning About Juxtapid Promotion But DOJ Probe Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Corrective broadcast clarifying statements its CEO made on CNBC’s “Fast Money” produces a close-out letter, but the firm emphasizes the cost and risks of a DOJ investigation.
You may also be interested in...
Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.
Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.